The TASTY-training Study (NCT07258589) | Clinical Trial Compass
RecruitingNot Applicable
The TASTY-training Study
Netherlands90 participantsStarted 2025-11-10
Plain-language summary
A multicentre non-blinded randomised intervention trial with a parallel cluster design. The multicentre study will be performed at 12 hospitals in the Netherlands. A parallel cluster design per hospital was selected to prevent contact between participants in the same hospital who are randomised into different study arms. Such contact may result in bias as it may allow for patients in the control arm to be informed about elements of taste and smell training.
To examine the effect of at-home taste and smell training versus standard care on taste function and other outcome parameters, measurements will take place at baseline (before the training starts), and after 12 weeks. The intervention will take place at home. The control group will receive usual care. Questionnaires will be filled in online at home, while taste and smell tests and saliva collection will be conducted either at home or in the hospital during regular visits. Patients in both study arms are contacted by their dietitian every 3 weeks.
Who can participate
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥18 and ≤70 years
* Intention of being treated with tyrosine kinase inhibitors for next 12 weeks.
* Experiencing taste alterations after starting treatment with tyrosine kinase inhibitors
* Consuming solid foods and drinks is possible
* ≤50% of recommended daily intake in kcal consisting of oral nutritional supplements
* Oral mucositis grade ≤2 (Common Terminology Criteria for Adverse Events, version 5.0)
* Ability to comply with all protocol-required actions
* Written informed consent
Exclusion Criteria:
* Pregnancy
* History of taste, smell, or saliva production dysfunction before treatment with tyrosine kinase inhibitors
* Previous or current radiotherapy of head and neck region
* Enteral feeding through tube or parenteral feeding
* Participation in another clinical trial aimed at preventing or treating taste and/or smell alterations
* Chronic (\>1 month) high dose corticosteroids (\>10 mg prednisone/day or equivalent)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.